Skip to main content

Peer Review reports

From: Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial

Original Submission
30 Nov 2021 Submitted Original manuscript
18 Mar 2022 Reviewed Reviewer Report - Muslim Syed
20 May 2022 Reviewed Reviewer Report - Hee Jin Kim
31 Jul 2022 Author responded Author comments - Nakwon Kwak
Resubmission - Version 2
31 Jul 2022 Submitted Manuscript version 2
3 Aug 2022 Author responded Author comments - Nakwon Kwak
Resubmission - Version 3
3 Aug 2022 Submitted Manuscript version 3
Publishing
3 Aug 2022 Editorially accepted
17 Aug 2022 Article published 10.1186/s13063-022-06631-z

You can find further information about peer review here.

Back to article page